sameAs
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairmentBrain imaging in Alzheimer diseaseDevelopment of positron emission tomography β-amyloid plaque imaging agentsImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-BUncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain.The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseMolecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memoryClinical and biomarker changes in dominantly inherited Alzheimer's disease.Markers of cholesterol transport are associated with amyloid deposition in the brain.Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults.In vivo assessment of amyloid-β deposition in nondemented very elderly subjectsClassification of amyloid-positivity in controls: comparison of visual read and quantitative approaches.The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's diseaseCognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia.Amyloid imaging in dementias with atypical presentation.Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease.Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice.Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2.Regional variability of imaging biomarkers in autosomal dominant Alzheimer's diseasePreclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.The role of biomarkers in clinical trials for Alzheimer diseaseVisualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34.Amyloid burden and neural function in people at risk for Alzheimer's Disease.Anti-Amyloid Effects of Small Molecule Aβ-Binding Agents in PS1/APP MiceAmyloid imaging in mild cognitive impairment subtypes.Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury.Positron emission tomography radioligands for in vivo imaging of Aβ plaques.Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals.A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain.Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers.Early detection of Alzheimer's disease using PiB and FDG PETPost-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's diseaseLongitudinal assessment of Aβ and cognition in aging and Alzheimer disease.Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's diseaseInter-rater reliability of manual and automated region-of-interest delineation for PiB PET.Development and screening of contrast agents for in vivo imaging of Parkinson's disease.Imaging of CNS myelin by positron-emission tomography.
P50
Q24648319-DC734868-3620-455C-B7B1-A72B36D109C2Q26996299-D1B64484-DD0A-49B6-92E4-A3B58C758C8DQ27012742-601532A1-76D0-40CC-8BBF-8044A73DA5E3Q29012704-FA8BF26C-F815-440C-9809-6E306CE0A0E8Q29302076-D3FD08BF-4934-4272-AF0B-0FAE0DF2776DQ29547554-AC95FAF5-EE44-410D-BB88-AF2351D571CBQ29614724-E8832767-F8C2-4EDC-A910-C293922559DEQ29619940-B4373B70-3E3F-42BF-8DBA-C167B0310CBDQ30406139-BABE0879-0B3C-4791-BB89-B1748182FABDQ30409644-E332108A-C0EB-4739-A4F2-E64A70F0F899Q30412704-E7F24AA8-BCAC-413F-BA78-958B39DD85C7Q30413572-2D54C5E2-7545-4E68-88F9-85FE61193DF1Q30413790-75365DC3-4139-4B41-AFDD-71FABD7155F8Q30413904-6ECC88AE-4055-4480-BCA2-69A89CB83B1DQ30417342-F28644D8-25A8-4937-A9AE-D8C90F1EE792Q30422060-6D5EA6C2-2C5D-4A59-BF95-49DBB702990FQ30426091-B6608528-A802-4FF2-8CB0-B222BE67FF80Q30436083-8F9BEC8D-A4A0-48B8-B828-3612A90AB538Q30481038-E34F0FCB-1CB5-4758-B870-8B7C7D2E8BCAQ30493972-25F82463-B39C-44D4-93C6-4939151E9E13Q30557788-4FE98E7E-B4F6-42BA-A381-8EB08F2BDF18Q30561855-C960E503-08D3-48BA-8BFB-C254D64113F4Q31032781-8B24D053-430B-4E59-AF17-2A23220511DBQ31968526-686AB181-6CC5-4C1B-ACB6-532A3A582B2CQ33599047-B1DA9D1C-345E-40F3-837B-153D7AEDEF89Q33616714-6B3EF1BC-16C1-48CD-A28C-2054598C9913Q33689424-6BA3773A-ED7F-4269-8733-B0DCB5C58078Q33856185-FF9E0253-A3BA-44E7-B523-CA7B0CD2DAF0Q33874024-40CFD48D-2E87-431D-A38A-2D7FCC59D2ABQ34012320-0523A356-04BE-4601-8FBC-C51EF1DCED79Q34111636-15080178-5941-4A2D-AE62-E644C84F7323Q34157492-B4987BC7-0500-485F-AB98-29327327BBA8Q34439071-814A9E4E-DDEC-48AC-BAE1-DA7DB6F5FE69Q34483878-9AAE268B-5F34-40FA-91B9-458DACD13E69Q34589414-41EDB65D-512C-4101-98D5-3C8936FCEBCEQ34606557-034436CF-D0E3-4B95-A58B-8E73825554B3Q34606568-C1345693-1FE5-40A7-9586-DC875F5BDC48Q34672421-04EB08A4-E80E-45EA-8E67-E07F133F7D8EQ34691754-6352F632-FAB7-4150-8E14-9E1CAD3C05E1Q34695082-93A9BE44-2CE0-4308-A227-FC07EF0A9B99
P50
description
neurologist
@en
psychiater
@nl
name
William E. Klunk
@ast
William E. Klunk
@en
William E. Klunk
@es
William E. Klunk
@nl
type
label
William E. Klunk
@ast
William E. Klunk
@en
William E. Klunk
@es
William E. Klunk
@nl
altLabel
Bill Klunk
@en
William E Klunk
@en
prefLabel
William E. Klunk
@ast
William E. Klunk
@en
William E. Klunk
@es
William E. Klunk
@nl
P166
P1153
7005237190
P166
P21
P31
P496
0000-0001-5512-0251